David P. Kodack

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

Helen Y. Zou, Luc Friboulet, David P. Kodack et al. · Cancer Cell · 2015 · 456 citations · Full text

Drug Target, Health Sciences, Preclinical Models +10

Fatty acid synthesis is required for breast cancer brain metastasis

Gino B. Ferraro, Ahmed Ali, Alba Luengo et al. · Nature Cancer · 2021 · 304 citations · Full text

Biochemistry, Fatty Acid Synthesis, Breast Cancer +3

Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms

Haichuan Hu, Zofia Piotrowska, Patricia J. Hare et al. · Cancer Cell · 2021 · 243 citations · Full text

Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care

David P. Kodack, Anna F. Farago, Anahita Dastur et al. · Cell Reports · 2017 · 201 citations · Full text

Cancer Management, Pathology, Cancer Registration +17

Combined targeting of HER2 and VEGFR2 for effective treatment of<i>HER2</i>-amplified breast cancer brain metastases

David P. Kodack, Euiheon Chung, Hiroshi Yamashita et al. · Proceedings of the National Academy of Sciences · 2012 · 152 citations · Full text